Is Protagonist Therapeutics, Inc. PTGX stock Halal to invest in?

Yes, as of September 2026, Protagonist Therapeutics, Inc. stock (PTGX) is classified as a Shariah compliant stock. Tabadulat applies AAOIFI Shariah Standard No. 21, issued by the Accounting and Auditing Organization for Islamic Financial Institutions, screening non-permissible income first and then the two interest-based ratios and the capital structure. On the latest data, Protagonist Therapeutics, Inc. passes on every count: non-permissible income under 5% of revenue, interest-bearing debt and investments each under 30% of market capitalisation, and no preference share issue. The stock's current purification factor is 97.08%. Compliance is reassessed every month as updated screening data arrives, and a stock's status can change when new financial reports are released. You can always check the current status of Protagonist Therapeutics, Inc. and explore other Shariah compliant stocks in the Tabadulat app.

How often is Protagonist Therapeutics, Inc. PTGX reviewed for Shariah compliance?

Tabadulat reviews Protagonist Therapeutics, Inc. PTGX for Shariah compliance every month. Each review applies the AAOIFI Shariah Standard No. 21 methodology, screening the company's business activities, non-permissible income, interest-bearing investments, interest-bearing debt, and preference shares, against the company's latest available financial data. The process operates under the direct supervision of Tabadulat's dedicated Shariah Supervisory Board of Islamic finance scholars. Because compliance depends on financial ratios that move with market capitalisation and reported results, a stock's status can change from one review to the next. Monthly screening ensures the status shown for Protagonist Therapeutics, Inc. reflects current financial data rather than an outdated assessment, and Tabadulat app users are notified if a holding in their portfolio becomes non-compliant.

Does Protagonist Therapeutics, Inc. PTGX pass the AAOIFI Non Permissible Income criteria?

Yes, as of September 2026, Protagonist Therapeutics, Inc. stock (PTGX) passes the AAOIFI non-permissible income screen. Under AAOIFI Shariah Standard No. 21, income from impermissible sources (such as interest or Riba, conventional financial services, alcohol, gambling, or tobacco) must remain below 5% of a company's total revenue. Protagonist Therapeutics, Inc.'s income from non-permissible sources is currently within this 5% threshold. Even permissible levels of incidental impure income should still be purified: investors donate the corresponding share of dividends to charity, as reflected in the stock's purification factor. This screen is reassessed monthly using the company's latest financial disclosures.

Does Protagonist Therapeutics, Inc. PTGX pass the AAOIFI Interest Bearing Investments criteria?

Yes, as of September 2026, Protagonist Therapeutics, Inc. stock (PTGX) passes the AAOIFI interest-bearing investments screen. Each month Tabadulat compares Protagonist Therapeutics, Inc.'s holdings in interest-earning instruments, such as conventional deposits, bonds and treasury bills, against AAOIFI's 30% market capitalisation cap. The current screening shows the company inside the limit. Because the ratio is measured against market capitalisation, it can move with the share price as well as the balance sheet, which is why Tabadulat rescreens the stock every month.

Does Protagonist Therapeutics, Inc. PTGX pass the AAOIFI Interest Bearing Debt criteria?

Yes, as of September 2026, Protagonist Therapeutics, Inc. stock (PTGX) passes the AAOIFI interest-bearing debt screen. AAOIFI tolerates some conventional borrowing but draws the line at 30% of market capitalisation. On the latest data, Protagonist Therapeutics, Inc.'s interest-bearing debt stays below the line. Because market capitalisation changes daily, a company's debt ratio can drift toward or away from the limit even without new borrowing, which is why this screen is reassessed every month.

What is the dividend purification factor for Protagonist Therapeutics, Inc. PTGX stock?

The dividend purification factor for Protagonist Therapeutics, Inc. (PTGX) stands at 97.08% in the September 2026 screening. In plain terms, 97.08% of a PTGX dividend is retained, and the remainder reflects incidental non-permissible income, typically interest on corporate cash, which Halal investors donate to charity (Tazkiyah). AAOIFI methodology asks for purification even on fully compliant stocks. The factor is recalculated with each monthly screening as new financial data arrives, and the Tabadulat app can help you calculate and track purification across your whole portfolio.

Does Protagonist Therapeutics, Inc. PTGX pass the AAOIFI Preference Share screen?

Yes, as of September 2026, Protagonist Therapeutics, Inc. stock (PTGX) passes the AAOIFI preference share screen. AAOIFI Shariah Standard No. 21 prohibits investing in preference shares because they grant holders guaranteed or priority rights to dividends and capital ahead of ordinary shareholders, a structure that conflicts with the Shariah principle that investors should share profit and loss in proportion to their ownership. Protagonist Therapeutics, Inc. has no impermissible preference share structure affecting its ordinary shares, so the stock is compliant on this criterion. Like all AAOIFI screens, this is verified in each monthly review.

Invest Halal, Anytime, Anywhere

Download the Tabadulat app and start building your Shariah-compliant portfolio in minutes.

English

العربية

Is Protagonist Therapeutics (PTGX) stock Halal?

NASDAQ

Shariah-Compliant

Not Shariah

September 2026 AAOIFI screening result for Protagonist Therapeutics, Inc. (PTGX): non-permissible income, pass. Interest-bearing investments, pass. Interest-bearing debt, pass. Preference shares, pass. Dividend purification factor: 97.08%. Re-screened monthly against AAOIFI Shariah Standard No. 21.

Sector:

Healthcare

Industry:

Biotechnology

Employees:

128

Website:

https://www.protagonist-inc.com

Market cap:

$9.5B

P/E ratio:

141.8

Dividend yield:

52-week range:

$54.50 - $160.81

Data as of:

3 September 2026

Screening history:

September 2026: PASS

Protagonist Therapeutics is a biopharmaceutical company dedicated to the discovery and development of peptide-based therapeutics. These therapeutics are designed to address significant unmet medical needs, focusing on diseases that involve critical biological pathways regulated by peptides and proteins. Utilizing a proprietary technology platform, Protagonist Therapeutics develops solutions for conditions such as inflammatory bowel disease, myeloproliferative neoplasms, and other serious health disorders. Before any of that matters to a Muslim investor, one question comes first: is Protagonist Therapeutics stock Halal?

Is Protagonist Therapeutics Shariah compliant?

The Shariah case on a technology company like Protagonist Therapeutics is rarely about the product. What AAOIFI Shariah Standard No. 21 examines is the money around the product: cash parked in instruments that earn Riba, borrowing measured against a market capitalisation that moves daily, and any incidental income from sources Islam prohibits, which must stay below 5% of revenue.

Does Protagonist Therapeutics pass the business activity test?

Yes. In the September 2026 screening Protagonist Therapeutics holds an overall PASS, which a stock only earns when its core business clears the activity screen. The watch item for technology names is incidental: cash returns and platform content can carry impermissible elements, which AAOIFI tolerates only below the thresholds.

Is Protagonist Therapeutics' income Halal?

Yes, within AAOIFI's tolerance. Protagonist Therapeutics' income from non-permissible sources stays below 5% of revenue in the September 2026 screening, and the small impure portion is handled through purification: the factor of 97.08% tells holders of PTGX what share of each dividend to keep and what remainder to donate to charity.

Does Protagonist Therapeutics meet AAOIFI's debt and investment ratio requirements?

Yes. Both caps hold this month: interest bearing investments and interest bearing debt each stay below 30% of market capitalisation. Because the caps move with the share price, our Shariah Supervisory Board has PTGX re-screened every month, and the result above always shows the latest verdict.

Tabadulat is an ADGM regulated brokerage whose license covers Shari'a Compliant Regulated Activities, as the FSRA permission names them. New to the terminology? Gharar and Maysir, Sukuk, Zakat and purification are all explained in plain English.

New to the four screens? Read Why a Halal Stock Screener Matters for Halal Investing

Frequently asked questions

Related stocks

Mobile login screen for Tabadulat with fields to enter email, a Continue button, an option to create an account, and a language selector showing EN.

Step 1

Open your account.

Create your Tabadulat account in minutes: enter your details, complete identity verification, and add funds by secure transfer in multiple currencies. You're ready to start investing in Halal stocks the same day.

Mobile screen showing add money interface with 100 AED amount and Manual Bank Transfer payment method selected, noting 1-2 business days processing.

Step 2

Deposit.

Add funds to your account using a secure payment method. You can deposit in multiple currencies to get started.

Step 3

Screen.

Screen Stocks for Free and explore a wide range of stocks that are ethically screened for Shariah compliance. Use our Halal Stock Screener to find the best opportunities.